' INTRODUCTION
Maintaining proper levels of tyrosyl phosphorylation through the reversible actions of protein tyrosine kinases (PTKs) and protein tryrosine phosphatases (PTPs) is vital for cellular processes ranging from growth and metabolism to adhesion and differentiation.
1,2 Deregulation of PTPs can be linked to diseases such as diabetes and cancer, and accordingly, this class of enzymes represents a new source of potential drug targets. 3À6 The Gram-negative enterobacterium Yersinia pestis (Y. pestis) has played an important role in human history as the causative agent of plague, 7 and more recently it has gained attention because of its possible use as a biological warfare agent. For pathogenicity, Y. pestis requires the virulence factor Yersinia pestis outer protein H "YopH", a highly active PTP. 8 Accordingly, potent and selective YopH inhibitors could provide a basis for new antiplague therapeutics. One difficulty encountered in the development of PTP inhibitors is a high incidence of "false positives" that can arise through inhibition of enzyme function by "promiscuous" mechanisms attributable to nonspecific factors such as protein aggregation. 9, 10 It is generally believed that promiscuous inhibitors do not represent valid leads, and avoiding promiscuous mechanisms is an important component of current drug development. 11 In theory, avoiding promiscuous behavior could be achieved through the use of substrates as templates for inhibitor design. This is because substrates must interact with their enzyme hosts in nonpromiscuous fashions in order for productive catalysis to occur. Employing small nonpeptidic arylphosphates to identify potential leads for PTP inhibitor design has been known for some time. 12À15 However, the explicit application of "substrate activity screening" for the purpose of minimizing misleading promiscuous inhibition has only more recently been proposed by Ellman for protease 16À20 and PTP targets. 21 This approach consists of first identifying substrates that exhibit high affinity, structurally enhancing these substrates, and then converting the optimized substrates to inhibitors by replacement of their labile phosphoryl groups with suitable nonhydrolyzable phosphoryl mimetics. Additional structural variations can then be performed to further increase inhibitory potency.
In the identification of high affinity substrates for the development of PTP inhibitors, advantage can be taken of the hydrolytic action of a PTP on an arylphosphate, which produces Received: January 10, 2011 ABSTRACT: Our current study reports the first K M optimization of a library of nitrophenylphosphate-containing substrates for generating an inhibitor lead against the Yersinia pestis outer protein phosphatase (YopH). A high activity substrate identified by this method (K M = 80 μM) was converted from a substrate into an inhibitor by replacement of its phosphate group with difluoromethylphosphonic acid and by attachment of an aminooxy handle for further structural optimization by oxime ligation. A cocrystal structure of this aminooxy-containing platform in complex with YopH allowed the identification of a conserved water molecule proximal to the aminooxy group that was subsequently employed for the design of furanyl-based oxime derivatives. By this process, a potent (IC 50 = 190 nM) and nonpromiscuous inhibitor was developed with good YopH selectivity relative to a panel of phosphatases. The inhibitor showed significant inhibition of intracellular Y. pestis replication at a noncytotoxic concentration. The current work presents general approaches to PTP inhibitor development that may be useful beyond YopH.
both the corresponding phenol and inorganic phosphate. Traditionally, the released inorganic phosphate can be quantified using colorimetric assays that employ phosphomolybdate 22, 23 or by secondary enzyme assays, including the use of purine nucleotide phosphorylase-mediated phosphate-dependent conversion of 2-amino-6-mercapto-7-methylpurine ribonucleoside to a derivative having an absorbance maximum at 360 nm. 24 It is also possible to spectrophotometrically measure the catalytically produced phenol. A variety of easily detected fluorescence-based substrates are known; 25 however, these agents would be of little value for the purpose of substrate activity screening and phenols derived from the more structurally diverse arylphosphates needed for substrate activity screening would typically exhibit very low extinction coefficients. 26 An exception to this is found with nitrophenols, which exhibit intense yellow color because of delocalization of the phenolate anionic charge. Because of this property, p-nitrophenylphosphate (pNPP) has become a ubiquitous substrate for monitoring the activity of phosphatases, including YopH. 8 In undertaking our current study, we desired to use direct spectrophotometric monitoring of phenol reaction products. For this purpose, we employed substrates (2) derived from either o-or p-nitrophenols (1, Figure 1 ). These compounds allowed the simple monitoring (absorbance at λ 405 nm) of yellow color resulting from the enzyme-catalyzed phosphoryl hydrolysis. Our utilization of nitrophenylphosphates represents the first systematic application of this structural class for PTP substrate optimization.
Once an inhibitor platform has been identified through a substrate activity approach, enhancement of affinity can be undertaken by introducing additional functionality intended to interact with sites proximal to the catalytic cavity.
27À33 A distinctive feature of the methodology in our current report is its incorporation of aminooxy functionality into the lead inhibitor platform (3) and the use of this handle for oxime-based derivatization (4, Figure 1 ). Functional group ligation by means of oxime bond formation can be considered to be a form of "click chemistry" 34 that we 35À38 and others 39À42 have shown can be highly useful for the facile generation of compound libraries. In the case of PTPs, azideÀalkyne Huisgen cycloaddition click reactions have been used previously for the rapid assembly of bidentate libraries targeting protein tyrosine phosphatase 1B (PTP1B) and Mycobacterium protein tyrosine phosphatase B (mPTPB). 43À45 However, a potential limitation of this type of click chemistry is the requirement for high throughput syntheses of azidecontaining libraries of reactants. 46 In contrast, oxime-based click chemistry is advantageous because it can be conducted using commercially available aldehydes and reaction products can be directly evaluated biologically without purification. As reported in our current paper, nitrophenylphosphate-based substrate activity screening used in combination with oxime ligation proved to be highly a successful approach that resulted in the development of a nonpromiscuous YopH inhibitor exhibiting a nanomolar IC 50 .
' RESULTS AND DISCUSSION Nitrophenylphosphate Substrates. A total of 48 o-and pnitrophenylphosphate-containing substrates (2) were prepared by phosphorylation (reaction with HPO 3 (Bn) 2 ) of either commercially available or synthetic nitrophenols, followed by TFAmediated cleavage of the resulting benzyl protecting groups. The YopH affinities of these substrates were determined using an in vitro assay that measured substrate turnover by monitoring the yellow color arising from the reaction product nitrophenols. 8 Color interference arising from sources other than the nitrophenol products did not prove to be problematic. Assay results for a subset of 11 selected substrates (2aÀk , Table 1 ) show that the 3-aminooxymethyl-containing substrate 2e exhibited a 3.5-fold decrease in its MichaelisÀMenten constant (K M = 170 μM) relative to pNPP (K M = 600 μM) while p-phenyl-o-nitrophenylphosphate (2j) showed an approximate 4-fold decrease in its K M (150 μM). The lowest K M was obtained with m-phenyl-pnitrophenylphosphate (2k, K M = 80 μM), which showed an approximate 7.5-fold decrease relative to reference pNPP.
Lead Inhibitor Platform 5. When substrates are used as structural models for inhibitor design, the interpretation of data from the substrate enzyme assays can be an important factor. In the current study, K M values were used to indicate substrate affinity. Previous comparisons of K M and k cat /K M for smallmolecule non-peptidyl aryl substrates have shown that K M values more closely reflect IC 50 and K i than do k cat /K M ratios.
12À14,21
On the basis of this consideration, substrate 2k was selected for conversion to an inhibitor because of its low K M .
In the conversion of a PTP substrate to an inhibitor, the choice of phosphoryl mimetic can have a dramatic effect on the resulting inhibitory potency. 21 In our current work R,R-difluoromethylphosphonic acid 47 was used as a phosphoryl replacement, since it is isosteric with the parent phosphate group and it has been shown to be one of the highest affinity phosphoryl replacements in PTP contexts (Scheme 1). 48, 49 A further consideration deals with the fate of the nitro functionality, since its role as a chromophore is no longer needed. Although an example has been reported where protein hydrogen bonding exists for the nitro group of a YopH-bound inhibitor, 50 in the current work the nitro functionality was removed at this stage. The transformation of 2k to the inhibitor platform 5 was completed by introduction of an aminooxy handle for use in preparing bidentate inhibitors (6) using oxime-based click chemistry (Figure 2 ).
34À42
Synthesis of Aminooxy-Containing Platform 5. The synthesis of 5 began with the CuBr and zinc promoted coupling reaction of diethyl (bromodifluoromethyl)phosphonate with 3-iodobromobenzene 51 to give the corresponding (difluoromethyl) phosphonic acid diethyl ester product 7 (Scheme 1). Suzuki coupling of 7 with 4-hydroxymethylboronic acid to give the biphenyl product 8 was followed by Mitsunobu reaction with Nhydroxyphthalimide and treatment of the resulting phthalimide with hydrazine hydrate to yield the aminooxy-containing diethylphosphonate 9 (79% yield). Finally, conversion of 9 to platform 5 was achieved through TMSBr-mediated phosphonate deprotection (Scheme 1). 52 Crystal Structure of YopH in Complex with Platform 5. In order to facilitate inhibitor optimization, the X-ray cocrystal structure of 5 bound to YopH was determined. The orientation of the phosphonodifluormethyl group of 5 within the catalytic pocket was observed to be highly similar to that previously reported for the phosphonodifluormethylphenylalanyl residue Journal of Medicinal Chemistry ARTICLE (F 2 Pmp) of the hexapeptide Ac-Asp-Ala-Asp-Glu-F 2 Pmp-Leuamide (PDB code 1QZ0) ( Figure 3A) . 53 The protein backbones of the two structures are nearly superimposable, and in both structures the flexible "WPD loops" (residues 354À356) are held in the "closed" conformation. For both structures the phosphoryl-mimicking difluoromethylphosphonic acid group is coordinated within the conserved (H/V)CX5R(S/T) signature motif "P loop" (residues 404À410) by six hydrogen bonds, 54À56 while the guanidine group of R409 forms two salt bridges with two phosphonic acid oxygen atoms and indirect hydrogen bonds with residues Q357, Q450, and Q446 are made through a conserved water residue (designated as "Wa1" for ligand 5 and "cw" in PDB 1QZ0). The 1-phenyl ring of 5 is pivoted about the difluoromethylene carbon so that it is offset, yet within the same plane relative to the F 2 Pmp aryl ring in the 1QZ0 structure. This allows the 3-(4 0 -methylphenyl) moiety of 5 to interact, similar to the Leu side chain of the dipeptide unit F 2 Pmp-Leu in the 1QZ0 structure ( Figure 3A ). The aryl rings of 5 form extensive hydrophobic contacts with residues F229, D231, I232, A405, Q446, and I443, similar to what is observed in the 1QZ0 structure ( Figure 3 and Table 2 ).
Introduction of Oxime Functionality into 5. In the cocrystal structure the aminooxyamine of 5 forms hydrogen bonds with the side chain carboxyl of D231 and a water molecule (Wa43), which also hydrogen-bonds to the D231 residue ( Figure 4A ). The importance of this latter water is indicated by its presence in the absence of inhibitor (designated as "Wa87" in PBD code 1LYV), suggesting that it could be used for inhibitor design. In silico docking studies performed using the cocrystal structure of 5 with the inclusion of Wa43 57,58 identified furanyl-based oximes as providing favorable interactions with the D231 residue through the intermediacy of the conserved water ( Figure 4B ).
Syntheses of a series of furanyl-based oxime inhibitors was performed in DMSO by reacting 5 (24 mM) with commercially available furanyl aldehydes and AcOH in the ratio (1:1:2). The oxime products (6), which were typically of >90% purity as shown by random HPLC analysis, were used directly for biological evaluation. Inhibitory potencies (IC 50 ) were obtained spectrophotometrically in an in vitro YopH assay using pNPP as substrate. 38 The 3-furanyloxime (6a) showed an IC 50 of 3.69 μM, whereas the 2-furanyloxime (6b) was approximately 3-fold more potent (IC 50 = 1.20 μM) ( Table 3) . In modeling studies, the furanyl oxygen in 6a 
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ARTICLE was seen to be at a greater distance from the conserved Wa43 than for 6b. Therefore, 6b was modified by sequential addition of a 5-methyl group (6c, IC 50 = 0.91 μM) and then by introduction of a hydroxyl group onto this methyl (6d, IC 50 = 0.73 μM) and finally by oxidation of the 5-hydroxymethyl substitutent to a carboxyl group (6e, IC 50 = 0.19 μM). This sequence of modifications resulted in a 6-fold improvement relative to the parent 6b. The observed binding enhancement of 6e was consistent with in silico docking studies that showed multiple interactions of its carboxyfuranyl oxime with the conserved Wa43 and with the backbone amide proton of R230 ( Figure 4C ). Examination of Specificity of 6e. The development of YopH inhibitors is less advanced than for several other phosphatases. For example, while the literature contains numerous reports of nanomolar-affinity PTP1B inhibitors, 59 there are few examples of YopH inhibitors exhibiting affinities in the submicromolar range. 30, 60 Additionally, the development of PTP inhibitors is plagued by a high incidence of false positives that are due to nonspecific or promiscuous mechanisms arising from the formation of colloid protein aggregates, 9, 10, 61, 62 and for some YopH inhibitors the possible roles of promiscuous mechanisms are unclear. The nanomolar IC 50 of 6e makes it one of the more potent YopH inhibitors reported to date. In order to determine whether promiscuous mechanisms are at work, assays were conducted in the presence and absence of 0.01% TX-100, since it is known that promiscuous inhibition can often be minimized by the addition of such a detergent. 62 These experiments showed that the inhibitory potency of 6e is independent of detergent concentration, providing strong evidence that YopH inhibition by 6e does not arise through promiscuous mechanisms.
It was also of interest to examine possible YopH selectivity of 6e, since significant structural homology exists among many phosphases. For this purpose, the inhibitory activity of 6e was measured against a panel of phosphatases that included the classical tyrosine-specific phosphatases PTP1B and leukocyte antigen related phosphatase (LAR), 63 as well as the dual specificity phosphatases 14 and 22 64 (DUSP14, DUSP22) and the Variola phosphatase VH1. In these assays 6e showed an approximate 17-fold selectivity for YopH relative to PTP1B and greater than 2000-fold selectivity relative to the other phosphatases examined (Table 4) .
Evaluation of 6e in Biological Models. A cell-based assay was used to assess toxicity of 6e. The mouse macrophage line J774 was cultured 40 h with 0.1À100 μM 6e, and toxicity was measured by cellular ATP content. No toxicity for any compound was observed for 6e below100 μM (data not shown). Intracellular replication of Y. pestis was assessed by a previously described human monocyte infection model. 65 Primary human monocytes were infected for 12 h with Y. pestis, using cell culture media containing 0.1À100 μM inhibitors or control. Specific inhibition of intracellular bacterial growth was observed with 10 μM 6e ( Figure 5 ). An approximately 9-fold decrease in intracellular bacteria resulted from treatment with 6e compared to a negative control that showed no inhibition of YopH. The positive control gentamycin (10 μM), which targets bacterial ribosomes, 66 produced nearly complete inhibition of intracellular Y. pestis growth.
' CONCLUSIONS
YopH has proven to be a difficult target for inhibitor development. While there are numerous reports of nanomolar affinity inhibitors against other phosphatases such as PTP1B, submicromolar affinity YopH inhibitors are very few. The current study represents the first utilization of a library of nitrophenylphosphate-containing substrates for the purposes of lead identification. An attractive feature of this approach is that K M can be calculated directly by colorimetric methods based on the enzymatic generation of nitrophenol chromophore-containing reaction products. The current work is also characterized by its use of oxime-based click ligation to optimize a substrate-derived lead. The combination of these two methodologies allowed the identification of a nonpromiscuous nanomolar affinity YopH inhibitor exhibiting good PTP selectivity that showed significant inhibition of intracellular Y. pestis replication at a noncytotoxic 
' MATERIALS AND METHODS
General. The following reagents used for YopH enzyme assays were obtained from Sigma-Aldrich: pNPP tablets, 30% BSA solution (protease free), 1.0 M HEPES solution (pH 7.0À7.6), and dithiotreitol (DTT). Aqueous ethylenediaminetetraacetic acid, sodium salt EDTA (0.5 M, pH 8.0) was obtained from Invitrogen, and 96-well plates were purchased from Costar. All reactions were carried out under argon unless otherwise stated. All solvents were anhydrous and obtained from Sigma-Aldrich. Final products were purified by a high pressure liquid chromatography (HPLC) using a Waters Prep-LC 4000 system and Phenomenex Gemini 10 μm, 110 Å C18 columns (250 mm Â 21.20 mm, 10 μm) at a flow rate of 10 mL/min (preparative HPLC) with a mobile phase of A = 0.1% aqueous TFA and B = 0.1% TFA in aqueous acetonitrile. Typical gradients were from 10% B to 100% B over 40 min with UV monitoring at 220, 254, and 280 nm. The purity of final products was determined by analytical HPLC using a Waters Prep-LC 4000 system and Phenomenex Gemini 5 μm, 110 Å C18 columns (250 mm Â 4.60 mm, 5 μm) at a flow rate of 1 mL/min with a mobile phase of A = 0.1% aqueous TFA and B = 0.1% TFA in aqueous acetonitrile. All final products were found to be g95% pure. NMR spectra were recorded using a Varian 400 MHz spectrometer. Unit mass resolution LCÀMS results were obtained on synthetic intermediates, and high resolution mass spectra were obtained for final products (University of California at Riverside Mass Spectral Facility). Optical densities were measured with Biotek Synergy 2 spectrophotometer at λ abs = 405 nm using a kinetic readout for determination of K M and absolute readout for determination of IC 50 . The PTPse domain of YopH (residues 164À468) was expressed in Escherichia coli according to a previously published procedure. 53 Recombinant Proteins. The PTPase domain of YopH (residues 164À468) was expressed in Escherichia coli and purified as described previously, 8, 53 as were the Variola major H1 (VH1) 67 and human DUSP-14 dual specificity phosphatases.
68 Human DUSP-22, PTP1B, and LAR catalytic domains were expressed and purified using generic methodology. 69 Determination of YopH MichaelisÀMenten Constants (K M ) for Nitrophenylphosphates. Total reactions volumes of 100 μL/well of reaction volume were used in 96-well plates. Buffer was prepared by mixing 25 mM Hepes buffer (pH 7.0À7.6), 50 mM NaCl, 2.5 mM EDTA, and 5 mM dithiothreitol (DTT) with 1 mM fresh DTT added right before an assay run. To each well was added 85 μL of assay buffer, 0.25% BSA (5 μL) followed by 5 μL of nitrophenylphosphate substrate in DMSO at dilutions of 1000, 500, 250, 125, 50, 25, 10, and 5 μM. To the reaction mixtures was then added 5 μL of YopH in buffer (25 μg/mL), and hydrolysis of substrate was monitored at 30 s intervals over 15 min. MichaelisÀMenten constants (K M ) were determined using nonlinear regression with the equation
Values for pNPP and synthetic substrates 2aÀk are shown in Table 1 . Data curves are provided in the Supporting Information.
Determination of YopH IC 50 Values. Total reactions volumes of 100 μL/well of reaction volume were used in 96-well plates. Buffer was prepared as above. To each well was added 79 μL of assay buffer, 0.25% BSA (5 μL) followed by 5 μL of inhibitors in DMSO at dilutions of 400, 133, 44, 15, 5, 1.67, 0.56, 0.19, 0.063, 0.032, and 0 μM. To the reaction mixtures was then added 5 μL of YopH in buffer (25 μg/mL) followed by 6 μL of 10 mM pNPP buffer, and each plate was agitated gently at 25°C for 15À20 min. Hydrolysis of the substrate was immediately measured. IC 50 values were determined by fitting the data with a sigmoidal curve generated using the Boltzman equation. A parallel independent assay was performed with 0.01% TritonX-100. Inhibition constants for 6aÀe are provided in Table 3 . Data curves are provided in the Supporting Information.
Toxicity Assay. Toxicity of 6e was assessed with the mouse macrophage line J774 (American Type Culture Collection, Manassas, VA), cultured in Eagle's minimum essential medium supplemented with 4 mM L-glutamine, 4500 mg/L glucose, 1500 mg/L sodium bicarbonate, and 7.5% fetal bovine serum (GIBCO/Invitrogen, Carlsbad, CA). Cells were grown in 96-well (5 Â 10 5 cells/100 mL) polystyrene plates (opaque bottom; Corning, Lowell, MA), maintained in a 5% CO 2 , humid air incubator (37°C). Inhibitor 6e was dissolved in DMSO to produce a 10 mM stock solution and then added to cultures by diluting in media to final concentrations of 0.1À100 μM. A negative control was also used that shows no inhibition of YopH. Culture media for all cells contained a final 1% DMSO, including control wells without chemical compounds. Cell viability was assessed by ATP content 20 and 40 h after treatment, using a commercial kit (ViaLight, Lonza, Basel, Switzerland) and a luminometer (Wallac 1420 Victor; PerkinElmer, Shelton, CT) to measure photon emission.
Intracellular Replication of Bacteria. Primary human monocyte cultures 65 were used to measure intracellular replication of the plague bacterium. The Y. pestis strain CO92 pgmÀ, plaÀ, was previously described. 70 Colony-isolated bacteria were grown for 12 h in heart-infusion 
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ARTICLE broth (HIB; Difco Laboratories, Detroit, MI) supplemented with 0.2% xylose and 2.5 mM CaCl 2 . A dilution of the culture was grown (26°C) to mid-log phase, and the bacteria were pelleted by centrifugation (600g) before rinsing with RPMI 1640 medium. Human peripheral blood monocytes (CD14þ) were isolated as previously described 65 and added (2 Â 10 5 /well) to tissue culture plates (96-well, flat bottom; Corning) in 100 μL of RPMI 1640 supplemented with 5% human AB sera (Life Technologies, Carlsbad, CA). The monocytes were incubated (1 h, 37°C) with a 1:1 ratio of Y. pestis in a 5% CO 2 , humid air incubator (37°C). The wells were pulsed with gentamycin (10 μg/mL, 20 min) and rinsed with warm media to remove remaining extracellular bacteria. The cells were then cultured for 12 h in a 5% CO 2 , humid air incubator (37°C) in media (100 μL of RPMI 1640 supplemented with 5% human AB sera) containing 0.1À100 μM 6e or a negative control that shows no inhibition of YopH. As a positive control, gentamycin was added to wells containing no other inhibitors. All cultures contained 1% DMSO by volume. The wells were then gently washed with warm medium, followed by addition of 120 μL of sterile distilled water to lyse the cells. The cell lysates were serially diluted (1:5) in HIB, and 200 mL of each dilution was placed into duplicate wells of a culture plate (Honeycomb; Growth Curves USA, Piscataway, NJ) and placed in a growth-monitoring incubator (Bioscreen; Growth Curves USA) with constant agitation (37°C). Bacterial growth was measured by optical density at 600 nm every 20 min for 16 h. The amount of Y. pestis was quantified by comparison to a standard curve of bacteria.
X-ray Crystallography. The purified protein was pooled and concentrated by diafiltration to 17.6 mg/mL in 100 mM sodium acetate, pH 5.7, 100 mM NaCl, and 1 mM EDTA. Crystals of YopH were obtained with condition D8 (0.1 M buffer system 2, pH 7.5, 0.12 M alcohols, 12.5% v/v MPD, 12.5% w/v PEG 1000, and 12.5% w/v PEG 3350) from the Molecular Dimensions (Apopka, FL) Morpheus screen.
71 A 1:1 ratio of protein (17.6 mg/mL) to well solution was used for crystallization at room temperature. Platelike crystals grew within 3 days. To obtain the proteinÀinhibitor complex, compound 5 was dissolved in DMSO and added to the crystallization solution to obtain a final concentration of 10 mM (10% DMSO). The crystals were added to the soaking solution and soaked for 48 h at room temperature. Crystals were flash-frozen in liquid nitrogen without the need of an additional cryoprotectant.
X-ray diffraction data for the YopHÀ5 complex were collected at beamline 22-ID of the SER-CAT facilities at the Argonne National Laboratory utilizing remote data collection. By use of 1.0 Å X-ray wavelength, 180 frames of data were collected using an exposure time of 3 s and oscillation angle of 1°. The X-ray diffraction data were processed with HKL3000. 72 Data collection and refinement statistics are outlined in Table 5 . The structure was solved by molecular replacement using the MOLREP program 73 from the CCP4 suite 74 and the coordinates of the previously solved YopH structure (PDB code 1QZ0) a Values were determined as described in Materials and Methods.
ARTICLE after removing all solvent and ligand atoms. Cross-rotation and translational searches were performed using data up to 3.0 Å followed by rigidbody refinement with REFMAC5. 75 Iterative rounds of model rebuilding and refinement were performed with COOT 76 and REFMAC5, and the location of the inhibitor was unambiguously identified using σ Aweighted 2mF o À DF c and mF o À DF c electron density maps. 77 The coordinates and refinement restraint files were prepared using the Dundee PRODRG server. 78 Water molecules were located using COOT and refined with REFMAC5. The refinement was monitored by setting aside 5% of the reflections for calculation of the R free value. 79 Model validation was performed using MolProbity. 80 The electron density map for YopH-bound inhibitor 5 is included in the Supporting Information. The coordinates and structure factor files were deposited in the Protein Data Bank with accession code 2Y2F.
In Silico Studies. Docking of inhibitors 6a and 6e onto YopH was done with ICM Chemist Pro software 57 running on a MacIntosh computer (OSX, version 10.5.8) using default parameters and procedures. 58 In summary, modeling started with the X-ray crystal structure of YopH in complex with 5. The "convert PDB" command was used to convert to native ICM format, with optimization of hydrogens. All H 2 O molecules were removed from the enzyme with the exception of the catalytically conserved water (Wa1) and a conserved water proximal to the ligand aminooxy group (Wa43) (see Figure 4A) . A 2-furanyl-based oxime group was added to the aminooxyamine of 5, and the resulting oxime structure (6a) was redocked using the "re-dock" option under the "Ligand" menu (see Figure 4B ). All docking experiments were performed using the standard "re-dock" command, which utilizes a rigid receptor protocol. The docked 6a was then modified by addition of a carboxyl group to the furanyl 5-position, and the resulting structure (6e) was redocked as described above (see Figure 4C ).
General Procedure for the Synthesis of Nitrophenylphosphate Substrates (2aÀk). To a solution of o-or p-nitrophenol (1.0 mmol) in CH 2 Cl 2 (5 mL) was added CCl 4 (5.0 mmol) at À15°C, and the reaction mixture was stirred at À15°C (5À10 min). To the mixture was added N,N-diisopropylethylamine (DIEA) (2.0 mmol) and N, N-dimethylaminopyridine (DMAP) (0.1 mmol). Then dibenzyl phosphite was added dropwise at À15°C, and the mixture was stirred at À15°C (1.5 h). The reaction was quenched by stirring with 0.5 M aqueous KH 2 PO 4 (20 mL) at room temperature (5 min). The aqueous phase was extracted with EtOAc, and the combined organic extract was dried (MgSO 4 ) and taken to dryness under reduced pressure. The resulting residue was stirred with a solution of TFA/CH 2 Cl 2 (1:1, 5 mL) for 2À3 h. Volatiles were removed by evaporation and crude products were subjected to HPLC purification to provide final products in yields of 75À100%. 2-Methyl-6-nitrophenyl Dihydrogen Phosphate (2g). a Values in parentheses are for reflections in the highest resolution shell.
4-(tert-Butyl)-2-nitrophenyl Dihydrogen Phosphate (2a).
, where AEI(hkl)ae is the mean intensity of multiply recorded reflections. c R = ∑|F obs (hkl) À F calc (hkl)|/∑ |F obs (hkl)|. R free is the R calculated for 5% of the data set not included in the refinement. Diethyl ((3-Bromophenyl)difluoromethyl)phosphonate (7) . A suspended solution of Zn dust (1.27 g, 19.4 mmol) in 3 mL of DMF was purged with argon. To this solution diethyl (bromodifluoromethyl)phosphonate (3.4 mL, 19.4 mmol) in 2 mL of DMF was added dropwise by maintaining reaction temperature at 50À60°C (reaction is exothermic). The reaction mixture was stirred at room temperature for over 3 h. CuBr (2.79 g, 19.4 mmol) was added, and the mixture was stirred for 30 min at room temperature. A solution of bromo-3-iodobenzene (2.00 g, 7.1 mmol) in 1 mL of DMF was added dropwise and was stirred for over 24 h at room temperature. Water (10 mL) and ether (10 mL) were added, and mixture was passed through Celite. The layers were separated, and the aqueous layer was extracted by ether. The organic extract was dried over MgSO 4 , filtered, and solvent was removed. The crude material was purified via silica gel column chromatography (9:1 to 2:1 hexanes/EtOAc) to give pale yellow oil product (2.3 g, 96% (8) . A mixture of 7 (500.0 mg, 1.46 mmol), (4-(hydroxymethyl)phenyl)boronic acid (332.0 mg, 2.19 mmol), and Pd(PPh 3 ) (84.0 mg, 0.07 mmol) in 5 mL of a saturated solution of K 2 CO 3 , 2 mL of EtOH, and 5 mL of toluene was purged with argon and stirred at 70°C overnight. Water (20 mL) was added upon cooling. The aqueous layer was extracted by EtOAc, and organic extract was dried over MgSO 4 , filtered. The solvent was removed under reduced pressure. Crude material was purified via silica gel chromatography (1.5:1 to 1:3 hexanes/EtOAc) to give 8 as a colorless oil (308 mg, 57% yield). , 1.30 mmol) . The mixture was stirred at room temperature for 4 h. The resulting precipitate was removed by filtration, and solvent was removed from the filtrate. The crude product was purified by silica column chromatography (50À100% EtOAc in hexanes) to yield 9 as an amorphous white solid (100 mg, 79% yield). 
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. To a solution of 9 (100 mg, 0.26 mmol) in anhydrous CH 2 Cl 2 (5 mL) under argon was added trimethylsilyl bromide (0.13 mL, 0.93 mmol), and the mixture was stirred at room temperature for 3 h. Solvent was removed, and HPLC purification was performed as described in the general synthetic methods section (retention time of 15.6 min) to provide 5 as an amorphous white solid (44.4 mg, 52% yield). Analytical HPLC gave 99% purity. ' REFERENCES
